Neurogene Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Neurogene Inc. (NGNE) holds an ST Score of 47.8 out of 100 (C+), with its strongest factor being Forecast (A) and its weakest Growth (F). Analysts rate NGNE Buy across 7 ratings with a $72.00 average price target (+1.2% vs the current $32.09).
- Strongest
- ForecastA
- Weakest
- GrowthF
All factor grades
- ForecastA
- Financial StrengthB+
- ValuationB
- MomentumB-
- ProfitabilityC+
- GrowthF
- Piotroski1/9
Contact
NGNE stock: frequently asked questions
What is NGNE's ST Score?
Neurogene Inc. (NGNE) has an ST Score of 47.8 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NGNE a buy, sell, or hold?
Wall Street's consensus rating on NGNE is Buy based on 7 analyst ratings. Our own ST Score grades it C+ (47.8/100). This is data, not investment advice — always do your own research.
What is NGNE's valuation grade?
Neurogene Inc. (NGNE) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NGNE's growth grade?
Neurogene Inc. (NGNE) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NGNE's profitability grade?
Neurogene Inc. (NGNE) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NGNE's financial strength grade?
Neurogene Inc. (NGNE) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NGNE?
The average analyst price target for Neurogene Inc. (NGNE) is $72.00 from 7 analysts, which is +1.2% versus the recent price of $32.09.
What is NGNE's Piotroski score?
Neurogene Inc. (NGNE) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.